title: Quantification of nucleated red blood cells in allogeneic marrow graft and impact of processing on recovery.
abstract: BACKGROUND
  In allogeneic bone marrow transplantation (BMT), a higher nucleated and CD34+ cell dose has been reported to improve various outcomes. Other cell types, such as lymphocyte subsets, also influenced BMT results. While nucleated red blood cells (NRBCs) represent a subset of bone marrow (BM) cell subpopulation, the question of their quantification in BM grafts and the impact of BM processing on their recovery has not been addressed.
  
  
  METHODS
  In a prospective study on 77 BM products, NRBCs were enumerated by flow cytometry and the recovery analyzed after manipulation. Because NRBCs could compromise white blood cell count, the impact of NRBC count on CD34+ cell percentage and total nucleated cell (TNC) dose were also determined.
  
  
  RESULTS
  The mean percentage of NRBCs in BM grafts was 21.6 percent (range, 7.8%-40.9%). Mean NRBC recoveries after BM concentration or RBC depletion were 98.4 and 28.7 percent, respectively, close to those obtained for TNC cells (88.6 and 31.3%, respectively). When corrected with NRBC count, the mean percentages of corrected CD34+ cell and TNC dose were significantly modified when compared with uncorrected values, whatever the type of BM manipulation.
  
  
  CONCLUSIONS
  Our data show that NRBC quantification might be of importance to improve quality control of BM products and to evaluate the influence of NRBCs cell dose on outcomes after BMT.
authors.affiliation: Cell Therapy Unit and the Bone Marrow Transplant Department, Public Assistance Hospitals of Paris, Saint-Louis Hospital, Paris, France.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Marolleau
authors.forename: Valérie
authors.initials: V
authors.lastname: Vanneaux
authors.forename: Delphine
authors.initials: D
authors.lastname: Rea
authors.forename: Brigitte
authors.initials: B
authors.lastname: Ternaux
authors.forename: Veronique
authors.initials: V
authors.lastname: Delasse
authors.forename: Valérie
authors.initials: V
authors.lastname: Hubert
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Chantre
authors.forename: Richard
authors.initials: R
authors.lastname: Traineau
authors.forename: Marie
authors.initials: M
authors.lastname: Robin
authors.forename: Marc
authors.initials: M
authors.lastname: Benbunan
authors.forename: Gerard
authors.initials: G
authors.lastname: Socié
authors.forename: Jérôme
authors.initials: J
authors.lastname: Larghero
mesh_terms: D000208:Acute Disease; D018952:Antigens, CD34 / Q000378:metabolism; D016026:Bone Marrow Transplantation / Q000379:methods* / Q000592:standards; D002467:Cell Nucleus; D002908:Chronic Disease; D004906:Erythrocyte Count; D004912:Erythrocytes; D005434:Flow Cytometry; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D011446:Prospective Studies; D011786:Quality Control; D020127:Recovery of Function; D012044:Regression Analysis; D014184:Transplantation, Homologous
chemical_list: D018952:Antigens, CD34